The Oxford / AstraZeneca Covid vaccine was approved by the Medicines and Health Products Regulatory Agency (MHRA) several months ago in the UK. Since then millions of doses of the AstraZeneca vaccine have been given to people in the UK. However, the vaccine rollout has not been without setbacks.
In recent weeks, the AstraZeneca vaccine has undergone extensive review for rare blood clots in recipients.
The latest MHRA data, released on April 15, explains that around 20.6 million first doses of the AstraZeneca vaccine were administered in the UK on April 5.
Until April 5, the MHRA had received Yellow Card reports of 100 cases of “major thromboembolic events (blood clots) with concomitant thrombocytopenia (low platelet count)” in the UK following vaccination with AstraZeneca jab.
The MHRA report added that the events occurred in 61 women and 39 men between the ages of 18 and 85.
READ MORE: Fatty liver disease: Study shows supplements decrease fat in liver
The overall case fatality rate from these events was 22 percent with 22 deaths.
In the UK, people under the age of 30 are now advised to receive an alternative vaccine to the AstraZeneca vaccine.
Other countries have also put in place age limits to determine who should receive the AstraZeneca vaccine.
However, for the vast majority of people, experts agree that the protection offered by the AstraZeneca vaccine against COVID-19 outweighs the risks.
Does AstraZeneca vaccine use mRNA?
Unlike the Pfizer / BioNTech and Moderna coronavirus vaccines, the Oxford / AstraZeneca vaccine is not an mRNA vaccine.
Instead, the AstraZeneca vaccine is a viral vector vaccine made from a weakened form of a common chimpanzee cold virus.
The genetic code for the SARS-CoV-2 spike protein is produced once inside the body.
The immune system then reacts and produces antibodies to help equip the body against an actual case of COVID-19 in the future.